North America Pharmaceutical Drug Delivery Market Segments and Growth by 2027

The North America pharmaceutical drug delivery market is anticipated to reach US$ 936,148.9 Mn by 2027 from US$ 560,491.5 Mn in 2019. The market is projected to grow at a CAGR of 6.8% during 2020–2027.

The growth of the market in this region is primarily ascribed to the increasing prevalence of chronic diseases. On the other hand, the high cost of developing drug delivery devices hinders the market growth. On the other hand, increasing spending in the R&D related to drug delivery devices is expected to fuel the growth of the North American pharmaceutical drug delivery market in the coming years. Pharmaceutical and medical devices companies are focusing on R&D to develop new molecules for various therapeutic applications and drug delivery platforms. They invest majorly on R&Ds with an aim to deliver high-quality and innovative products. R&D spending by the biopharmaceutical companies has also increased over the years. According to a report of Pharmaceutical Research and Manufacturers of America (PhRMA), the R&D expenditure of the biopharmaceutical companies increased from US$ 49.6 billion 2012 to US$ 58.8 billion in 2015. Evonik Corporation has invested more than US$ 50 million over the last 4 years to advance its competencies in the medical devices market as well as in the marketplace for RESOMER polymers for drug delivery and bioreabsorbable medical devices.

Additionally, the companies are engaged in establishing new collaborations and partnerships for the development of new drug delivery systems. For instance, in December 2018, IntelGenx Corp., a leading oral drug delivery company, entered into a strategic collaboration with Gensco Pharma for the commercialization of RIZAPORT in the US. The newly approved device would be the first oral thin film to be used in the treatment of migraines. In April 2020, Revive Therapeutics announced research partnership with the University of Wisconsin-Madison to develop novel formulations and drug delivery technologies.

In 2019, the US accounted for the largest share in North America pharmaceutical drug delivery market, and it is also expected to grow at a faster pace over the forecast period. The US is an economically advanced country, and it leverages the presence of various well-established pharmaceutical market players. Increasing prevalence of chronic diseases such as diabetes and asthma, growing number of product launches by key players, and increasing use of drug delivery devices for disease management are among the key factors driving the country toward the largest market share.

US Pharmaceutical Drug Delivery Market, Revenue and Forecast to 2027 (US$ Mn)

NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET SEGMENTATION

By Route of Administration

• Oral Drug Delivery
• Injectable Drug Delivery
• Topical Drug Delivery
• Ocular Drug Delivery
• Pulmonary Drug Delivery
• Nasal Drug Delivery
• Transmucosal Drug Delivery
• Implantable Drug Delivery

By Application

• Infectious Diseases
• Cancer
• Cardiovascular Diseases
• Diabetes
• Respiratory Diseases
• Central Nervous System Disorders
• Autoimmune Diseases
• Other Applications

By End User

• Hospitals
• Home Care Settings
• ASC/Clinics
• Other End Users

By Country

• North America

• • US
  • Canada
  • Mexico

Company Profiles

• 3M
• Antares Pharma
• BD
• Pfizer Inc.
• Johnson & Johnson Services, Inc.

North America Pharmaceutical Drug Delivery Report Scope